NCT04591600

Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients

Completed Phase 1, PHASE2 Last updated 19 October 2020

What this trial tests

Phase 1, PHASE2 trial testing Ivermectin and Doxycyline in Covid19 in 140 participants. Completed in 14 October 2020.

Timeline

1 July 2020

Primary endpoint
30 September 2020

14 October 2020

Quick facts

Lead sponsor	Alkarkh Health Directorate-Baghdad
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	140
Start date	1 July 2020
Primary completion	30 September 2020
Estimated completion	14 October 2020
Sites	1 location across Iraq

Drugs / interventions tested

• Ivermectin and Doxycyline — full drug profile →
• Standard of care

Conditions studied

• Covid19 — all drugs for Covid19 →

Sponsor

Alkarkh Health Directorate-Baghdad — full company profile →

Who can join

Adults 16 to 86, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized controlled trial on using Ivermectin and doxycycline to treat mild-moderate outpatients, severe, and critical inpatients of Coronavirus disease 19 (COVID-19) along with standard of care. Seventy Iraqi COVID-19 patients received Ivermectin and Doxycycline plus standard of care versus seventy Iraqi COVID-19 patients received standard of care only. .

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
   Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
2. Potential molecular mechanisms of zinc- and copper-mediated antiviral activity on COVID-19.
   Rani I, Goyal A, Bhatnagar M, Manhas S, et al · · 2021 · cited 43× · PMID 34284268 · DOI 10.1016/j.nutres.2021.05.008
3. Development of Therapeutic and Prophylactic Zinc Compositions for Use against COVID-19: A Glimpse of the Trends, Inventions, and Patents.
   Imran M, Fatima W, Alzahrani AK, Suhail N, et al · · 2022 · cited 13× · PMID 35334884 · DOI 10.3390/nu14061227
4. Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.
   Raghav PK, Mann Z, Ahluwalia SK, Rajalingam R. · · 2023 · cited 11× · PMID 37059487 · DOI 10.1016/j.jphs.2023.02.004
5. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq
   Hashim HA, Maulood MF, Rasheed AM, Fatak DF, et al · · 2020 · cited 8× · DOI 10.1101/2020.10.26.20219345
6. Putative COVID-19 therapies imatinib, lopinavir, ritonavir, and ivermectin cause hair cell damage: A targeted screen in the zebrafish lateral line.
   Coffin AB, Dale E, Doppenberg E, Fearington F, et al · · 2022 · cited 6× · PMID 36090793 · DOI 10.3389/fncel.2022.941031
7. A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status.
   Chowdhury A, Sajid M, Jahan N, Adelusi TI, et al · · 2021 · cited 6× · PMID 34332377 · DOI 10.1016/j.biopha.2021.111956
8. Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies.
   Muthukutty P, MacDonald J, Yoo SY. · · 2024 · cited 5× · PMID 39591123 · DOI 10.3390/vaccines12111220